Obtain a PDF overview of our company and offerings.
Digital biomarkers have brought new levels of speed and accuracy to the world of Parkinson’s clinical trials, producing better data with the potential to accelerate clinical trial timelines with increasingly confident decisions.
Koneksa stands at the forefront of this evolution, developing and validating digital biomarkers enhanced by cutting-edge algorithms for early signal detection and built for specific therapeutic considerations, such as Parkinson’s disease. Alongside a configurable SaaS platform, Koneksa is uniquely suited to provide advanced therapeutic effect detection solutions and quicker, more actionable results for Parkinson’s disease research.
Our science-driven approach results in highly specialized digital biomarkers designed for faster, more comprehensive data collection. This allows for early signal detection as well as optimal patient centricity for exceptional compliance and a more complete picture of each patient and data set.
Additionally, our digital measures benefit from more objective remote data collection that minimizes human bias and error, as traditional assessments are subjective, relying on the clinician to correctly quantify tremor level or balance changes. Our digital biomarkers garner timely, accurate reporting of the measures that matter, resulting in quicker, deeper insights at every level.
Seamless remote data collection leveraging trusted digital health technology — lowers patient burden, increases convenience, and improves compliance
Evidence that guides for future success in Parkinson’s research — thorough data sets that show which protocols produced the most compliance
A dynamic, device-agnostic platform — crucial for a disease with vast symptoms and no “average patient”
Clearer data capture — faster, more comprehensive data for more confident decision-making
A higher standard in quality data — a higher frequency of collection than MDS-UPDRS and other standard measures
More robust proprietary algorithms — aligned with innovative capabilities to produce better data in less time
Koneksa is THE digital biomarker company, leading and defining how the life sciences industry uses digital measurement solutions to transform clinical research in a precise and clinically robust manner. Going far beyond conventional eCOAs, our offerings include user-friendly, app-based functional assessments, passively collected wearable sensor data, and a configurable, SaaS study execution platform to support seamless compliance monitoring, data integration, and device provisioning.
The future of Parkinson’s research will be defined by continuous remote data collection that not only respects the needs of Parkinson’s patients but also produces more meaningful everyday clinical measures for study endpoint analysis and milestone evaluation. It will be defined by better data and faster results — made possible by Koneksa’s digital biomarkers.
Koneksa Health partnered with Sanofi to develop a digital endpoint instrument for PD research to simplify data collection and management, accelerate therapeutic development, and ease study participation burdens for patients. Download the case study now to explore this novel endpoint solution and its implications for the future of PD research.